References
- 1. Seyama Y, Kokudo N. Assessment of liver function for safe hepatic resection. Hepatol Res. 2009; 39: 107-16.10.1111/j.1872-034X.2008.00441.x
- 2. Manizate F, Hiotis SP, Labow D, Roayaie S, Schwartz M. Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology. 2010; 78: 131-4.10.1159/000315241
- 3. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000; 31:864-71.10.1053/he.2000.5852
- 4. Botta F, Giannini E, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. 2003; 52:134-9.10.1136/gut.52.1.134
- 5. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33:464-70.10.1053/jhep.2001.22172
- 6. Hamm B, Staks T, Muhler A, Bollow M, Taupitz M, Frenzel T, et al. Phase I clinical evaluation of Gd- EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995; 195:785-92.
- 7. Reimer P, Rummeny EJ, Shamsi K, Balzer T, Daldrup HE, Tombach B, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996; 199:177-83.
- 8. Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology. 2005; 237: 89-98.
- 9. Ryeom HK, Kim SH, Kim JY, Kim HJ, Lee JM, Chang YM, et al. Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol. 2004; 5:231-9.10.3348/kjr.2004.5.4.231
- 10. Tajima T, Takao H, Akai H, Kiryu S, Imamura H, Watanabe Y, et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2010; 34:362-6.
- 11. Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol. 2011; 46:277-83.10.1097/RLI.0b013e318200f67d
- 12. Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, et al. Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging. Eur J Radiol. 2012; 81:1460-4.10.1016/j.ejrad.2011.03.073
- 13. Tamada T, Ito K, Higaki A, Yoshida K, Kanki A, Sato T, et al. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol. 2011; 80:e311-6.10.1016/j.ejrad.2011.01.020
- 14. Nakamura S, Awai K, Utsunomiya D, Namimoto T, Nakaura T, Morita K, et al. Chronological evaluation of liver enhancement in patients with chronic liver disease at Gd-EOB-DTPA-enhanced 3-T MR imaging: does liver function correlate with enhancement? Jpn J Radiol. 2012; 30:25-33.
- 15. Verloh N, Haimerl M, Zeman F, Schlabeck M, Wiggermann P, et al. Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla. Eur Radiol. 2014; 24:1013-9.10.1007/s00330-014-3108-y